Trial Profile
A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer
Status:
Discontinued
Phase of Trial:
Phase 0
Latest Information Update: 19 Mar 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Paricalcitol (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- 19 Apr 2022 Status changed from active, no longer recruiting to discontinued as the accrual goal could not be met and the drug manufacturer pulled support.
- 18 Mar 2022 Status changed from recruiting to active, no longer recruiting.
- 29 Jul 2020 Status changed from not yet recruiting to recruiting.